

FORWARD thinning/thickening manuscript\_Final draft\_July 2019

**Supplementary Table S1** Baseline characteristics in patients with baseline and 24-month MRI data (mITT population)

	Placebo (n=83)	Sprifermin			
		30 µg q12mo (n=92)	30 µg q6mo (n=83)	100 µg q12mo (n=90)	100 µg q6mo (n=86)
Median age, years (range)	65.0 (41–83)	67.0 (41–80)	65.0 (42–80)	65.0 (41–80)	67.0 (44–80)
Female, %	69.9	68.5	69.9	70.0	68.6
White race, %	79.5	77.2	77.1	77.8	81.4
Median BMI, kg/m <sup>2</sup> (range)	28.1 (20.4–43.5)	28.6 (18.6–51.3)	27.4 (18.6–44.5)	28.2 (17.5–43.5)	29.1 (21.7–43.3)
KLG2, % <sup>a</sup>	69.9	66.3	69.9	67.8	70.9
Predominately medial, % <sup>b</sup>	63.8	65.9	67.9	68.6	73.8
OARSI JSN score (medial or lateral), % <sup>b,c</sup>					
0	36.3	37.5	44.4	45.3	39.3
1	41.3	39.8	39.5	37.2	38.1
>1	22.5	22.7	16.0	17.4	22.6
Median time since diagnosis, years (range) <sup>a</sup>	7.0 (1–39)	7.0 (1–30)	7.0 (1–35)	7.0 (1–24)	6.0 (2–42)
Mean medial mJSW, mm (SD) <sup>a</sup>	4.3 (1.33)	4.1 (1.09)	4.3 (1.29)	4.3 (1.29)	4.2 (1.09)
Mean TFTJ cartilage thickness, mm (SD) <sup>a</sup>	1.81 (0.27)	1.78 (0.22)	1.82 (0.27)	1.81 (0.27)	1.80 (0.26)
Mean WOMAC Q1 (SD) <sup>a</sup>	5.7 (1.43)	5.6 (1.41)	5.6 (1.34)	5.5 (1.13)	5.9 (1.27)

<sup>a</sup>In the target knee; <sup>b</sup>In a subset of patients where readings were available; <sup>c</sup>Maximum JSN score for both medial and lateral compartments.

Total qMRI cartilage thickness = Total volume divided by total surface area (ie, average cartilage thickness).

BMI, body mass index; JSN, joint space narrowing; KLG, Kellgren-Lawrence grade; mJSW, minimum joint space width; mITT, modified intention-to-treat; OARSI, Osteoarthritis Research Society International; q6mo, every 6 months active cycle; q12mo, every 12 months active cycle; qMRI, quantitative magnetic resonance imaging; SD, standard deviation; TFTJ, total femorotibial joint; WOMAC, Western Ontario and McMaster Universities Osteoarthritis.

JSN Scores: 0 = normal, 1 = mild, 2 = moderate, and 3 = severe.